Banner for leaf pages 2

Ruxolitinib (Jakafi)

Also known as Jakafi

Ruxolitinib (trade names Jakafi and Jakavi, by Incyte Pharmaceuticals and Novartis) is a drug for the treatment of intermediate or high-risk myelofibrosis, a type of bone marrow cancer. It is also being investigated for the treatment of other types of cancer (such as lymphomas and pancreatic cancer), for polycythemia vera, and for plaque psoriasis.

Source: Wikipedia

What is it prescribed for?

Patients are most commonly prescribed ruxolitinib to treat rabies, blastomycosis, west nile virus, and pick disease.

What drug interactions are known?

Do not take ruxolitinib if you are taking any of the following:

Critical Interactions


Significant Interactions

Ajax-loader Loading...